Skip to main content
OpenTrials
Completed

NCT Number: NCT00402116

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

There will be 2 phases in this study. Patients will either be enrolled to the first phase or to the second phase, depending upon when they enroll into the study.

The first phase of this study is done to evaluate the safety of enzastaurin in patients. This is done by gradually increasing the dose of the drug in small groups of patients and watching closely for side effects.

In the second phase of the study, the dose determined to be safe will be used with temozolomide during and following radiation therapy to see if the combination can help patients with brain tumors live longer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Glioblastoma Multiforme Glioma Gliosarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

San Francisco, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have a histologically confirmed diagnosis of intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS).
  • Biopsy or resection must have been performed no more than 5 weeks prior to treatment.
  • An MRI or CT scan must be obtained within 14 days prior to treatment.
  • Patients must not have received prior drug therapy for brain tumors.
  • Patients must have adequate organ function demonstrated by lab tests within 14 days prior to treatment.

Exclusion criteria

  • Patients will be excluded if unable to swallow tablets.
  • Patients will be excluded if unable to discontinue use of enzyme inducing antiepileptic drugs or have been off of these agents less than 2 weeks prior to treatment (i.e. phenytoin (Dilantin®), carbamazepine, etc.).
  • Patients will be excluded if have active infection.
  • Patients will be excluded if have a significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
  • Patients will be excluded if they have concurrent therapy with an anticoagulant. If the patient requires anticoagulant therapy after starting treatment, the patient may remain on study but should be monitored carefully.

Treatment and study plan

enzastaurin

Drug

Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles

Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles

Other names: LY317615

Temozolomide

Drug

75 milligrams per meter squared (mg/m^2), oral, daily, 6 weeks then 200 mg/m^2, oral, daily, twelve 28 day cycles

radiation therapy

Radiation

1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks

Primary outcomes

  1. Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin

    Time frame: Until MTD can be determined (up to 12 cycles, 28 days per cycle)

    Phase 1- dose escalation of enzastaurin in 2 cohorts up to 6 participants each in order to assess MTD. After radiation/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy, if no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) or tumor progression, participants completed one 28-day cycle. If no significant toxicity after the first cycle, participants received subsequent cycles. If no more than 1 of the 6 patients treated at 250 mg of enzastaurin experienced a DLT, up to 6 more patients could be entered at escalated dose cohort of enzastaurin (500 mg).

  2. Phase 1 and Phase 2 - Overall Survival (OS)

    Time frame: Baseline to death from any cause (Up to 48 weeks)

    OS is the time from surgical diagnosis to the date of death from any cause. For participants who were alive, OS was censored at the last contact.

Secondary outcomes

  1. Phase 1 - Number of Participants With Adverse Events (AEs)

    Time frame: Every cycle (up to 12 cycles, 28 days per cycle)

    Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

  2. Phase 1 and 2: Association Between Biomarkers and Clinical Outcome

    Time frame: Baseline, Cycle 2, end of study (up to 12 cycles, 28 days per cycle)

    Phosphorylated-S6 (pS6) ribosomal protein is a biomarker that's being investigated as a potential marker for clinical outcome using 2211 or 2215 antibody to pS6. Reported here are the hazard ratios and 95% confidence intervals (CIs) for participants for whom an pS6 immunohistochemistry (IHC) score was available. The IHC assays were scored using a 0 to +3 scoring system (no positive staining was scored 0; at least 25% immunoreactivity of cells was scored +1; 26% to 75% was scored +2; and 76% or greater was scored +3). Hazard ratio (HR) > 1 indicates worse outcome for that IHC score.

  3. Phase 1 - Response Rate With Macdonald Criteria

    Time frame: Baseline, following radiation, every other cycle (up to 12 cycles, 28 days per cycle)

    Response categories: complete response (CR): disappearance of all enhancing tumor on consecutive magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved. Partial response (PR): 50% reduction in size of enhancing tumor on consecutive MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. Progressive disease (PD): >25% increase in size of enhancing tumor or any new tumor on MRI scans, or neurologically worse, and steroids stable or increased. Stable disease (SD): all other situations.

  4. Phase 2 - Number of Participants With Adverse Events (AEs)

    Time frame: Every cycle (28 days per cycle)

    Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.

  5. Number of Participants Undergoing Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy (MRI/MRS) for Clinical Evaluation at Baseline

    Time frame: Each radiologic assessment (up to 12 cycles, 28 days per cycle)

    Number of patients having MRI/MRS for clinical evaluation with baseline assessment.

  6. Phase 1 and 2 - Progression-Free Survival (PFS)

    Time frame: Baseline to measured progressive disease (up to 12 cycles, 28 days per cycle)

    PFS was defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.

  7. Functional Assessment of Cancer Therapy - Brain (FACT-Br)

    Time frame: Every cycle (up to 12 cycles, 28 days per cycle)

    Total FACT-Br score includes physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns related to brain tumors. The score ranges 0 to 200, with a higher score representing better quality of life.

  8. M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)

    Time frame: Every cycle (up to 12 cycles, 28 days per cycle)

    General and brain tumor-specific symptoms each assessed on a scale of 0 to 10, with a higher score representing higher symptom burden. The 4 symptom scales reported as changing over the course of the study are listed here.

  9. Phase 1- Pharmacokinetics (PK): Maximum Observed Drug Concentration During 1 Dosing Interval at Steady State (Cmax,ss) for Enzastaurin, LY326020, and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide

    Time frame: Cycle 1 Day 22, Cycle 2 Day 5, 28 days per Cycle

    Cmax,ss was calculated using concentration versus time data of enzastaurin, LY326020, and Total Analyte (enzastaurin + LY326020) when 250 mg or 500 mg enzastaurin was administered alone or with 75 mg/m^2 temozolomide. Data are reported as Geometric Mean and Geometric Coefficient of Variation (%).

  10. Phase 1 and 2- Pharmacokinetics: Area Under the Concentration-Time Curve During 1 Dosing Interval at Steady State (AUCτ,ss) for Enzastaurin, LY326020 and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide

    Time frame: Phase 1, Cycle 1 Day 22, Cycle 2 Day 5 of a 28 day Cycle; Phase 2, Cycle 1 Day 22 of a 28 day Cycle

    AUCτ,ss was calculated using concentration versus time data of enzastaurin, LY326020, and total analyte (enzastaurin + LY326020). Data are reported as Geometric Mean and Geometric Coefficient of Variation (%).

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Collaborators

  • University of California, San Francisco

Registry information

Official study title

Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Nov 22, 2006
Registry last updated
Aug 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.